Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

6.890 +0.280 (+4.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Sage Therapeutics Inc (SAGE) Q2 2021 Earnings Call Transcript
SAGE earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Sage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval
Tucked in the Q2 earnings release, Sage Therapeutics Inc (NASDAQ: SAGE) has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder (MDD).... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands (NYSE:LVS) was the largest firm by market cap to set a new 52-... 
Via Benzinga
Analyst Ratings For Sage Therapeutics
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Sage Therapeutics: Q2 Earnings Insights
Shares of Sage Therapeutics (NASDAQ:SAGE) moved higher by 11.9% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 12... 
Via Benzinga
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap... 
Via Benzinga
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
From Sage Therapeutics, Inc.
Via Business Wire
June’s Best and Worst Performing Russell 1,000 Stocks
The month of June, the second quarter and the first half of 2021 are almost in the bag. 
Via Talk Markets
How Bad Is Biogen's Latest Bad News?
The drugmaker has had one big clinical setback and another less serious disappointment in recent weeks. 
Via The Motley Fool
Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum
From Sage Therapeutics, Inc.
Via Business Wire
What Happened to Sage Therapeutics Stock?
Sage has been struggling for some time to bring its flagship antidepressant to the market. 
Via The Motley Fool
Looking For Bargains Among The Rubble
Last week was tough. Nearly everything publicly traded took a hit. In this article I drill down into the market to take account of where the damage was the worst, and maybe identify a few bargains... 
Via Talk Markets
Here's Why Sage Therapeutics Tanked This Week
The neuroscience-focused biotech company didn't give investors the result they wanted. 
Via The Motley Fool
Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops
Biogen Inc (NASDAQ: BIIB) has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned. The... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2021
Upgrades According to Piper Sandler, the prior rating for First Bancorp (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Morgan Stanley raised NIKE, Inc. (NYSE:NKE) price ta... 
Via Benzinga
44 Biggest Movers From Yesterday
Gainers Alzamend Neuro, Inc. (NASDAQ: ALZN) shares jumped 170% to close at $13.50 on Tuesday after the company priced its IPO at $5 per share. Alfi, Inc. (NASDAQ: ALF) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Mid-Afternoon Market Update: Nasdaq Down 100 Points; Clearside Biomedical Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.19% to 34,326.95 while the NASDAQ fell 0.70% to 14,074. The S&P also fell, dropping 0.12% to 4,249.99. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock moved upwards by 26.21% to $3.81 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
Here's Why Sage Therapeutics Stock Is Sliding Today
Long-awaited clinical trial results weren't as successful as hoped. 
Via The Motley Fool
Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide
Midway through trading Tuesday, the Dow traded down 0.45% to 34,238.18 while the NASDAQ fell 0.53% to 14,099.27. The S&P also fell, dropping 0.25% to 4,244.45. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers HMG/Courtland Properties, Inc. (NYSE: HMG) shares surged 133% to $27.80. Alfi, Inc. (NASDAQ: ALF) shares jumped 82.1% to $6.21 after the company inked an agreement with... 
Via Benzinga
Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug
Biogen Inc. (NASDAQ: BIIB) stock is seeing muted sentiment Tuesday as it emerges from the euphoria over Aduhelm approval, with the most recent trigger being lukewarm data for a... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May
Following the market opening Tuesday, the Dow traded down 0.34% to 34,275.92 while the NASDAQ fell 0.09% to 14,161.73. The S&P also fell, dropping 0.10% to 4,250.89. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Sage Stock Tumbles As Analysts Question Its 'Positive' Test In Depression
The results showed an improvement over placebo. But that improvement waned over time. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS